专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2009125987A3 PHARMACEUTICAL FORMULATION 审中-公开
标题翻译：药物制剂
公开(公告)号：WO2009125987A3
公开(公告)日：2009-12-03
申请号：PCT/KR2009001833
申请日：2009-04-09
申请人： HANALL PHARMACEUTICAL CO LTD , KIM SUNG WUK , JUN SUNG SOO , JO YOUNG GWAN , KOO JA SEONG , SUN SANG OUK , KIM JEONG TAEK , LEE AH RAM , CHOI JIN WON , JANG SEOK YOUNG , KIM BYUNG HA , KIM JIN WOOK , NAM TAE YOUNG , LEE KEEL HO
发明人： KIM SUNG WUK , JUN SUNG SOO , JO YOUNG GWAN , KOO JA SEONG , SUN SANG OUK , KIM JEONG TAEK , LEE AH RAM , CHOI JIN WON , JANG SEOK YOUNG , KIM BYUNG HA , KIM JIN WOOK , NAM TAE YOUNG , LEE KEEL HO
IPC分类号： A61K9/22 , A61K9/16 , A61K9/48 , A61K31/41 , A61K31/4184 , A61P9/12
CPC分类号： A61K31/41 , A61K31/4184
摘要： The present invention relates to a pharmaceutical formulation containing an extended-release compartment having a dihydropyridine calcium channel blocker and an immediate-release compartment having an angiotensin-2 receptor blocker. The present invention provides the pharmaceutical formulation in which the dihydropyridine calcium channel blocker and angiotensin-2 receptor blocker are separately contained in each compartment and of which release is controlled. Since each different drug contained in each different compartment of the formulation is released at a different time, the pharmaceutical formulation of the present invention minimizes the antagonism and side effects between drugs and maximizes the specific effect of the drugs. The pharmaceutical formulation by the specific combination between the two drugs according to the present invention has remarkably good effects in treating or preventing diseases compared with the single administration of each of the drugs or the simple combined administration of the drugs.
摘要翻译：本发明涉及含有具有二氢吡啶类钙通道阻滞剂的延长释放室和具有血管紧张素-2受体阻断剂的立即释放室的药物制剂。本发明提供了药物制剂，其中二氢吡啶类钙通道阻滞剂和血管紧张素-2受体阻断剂分别包含在每个隔室中，并且其释放被控制。由于制剂的每个不同隔室中包含的每种不同药物在不同的时间被释放，所以本发明的药物制剂使药物之间的拮抗作用和副作用最小化并使药物的具体效果最大化。根据本发明的两种药物之间的具体组合，通过与各药物的单次给药或药物的简单组合给药，治疗或预防疾病具有显着的效果。

2. 发明申请

WO2009125987A2 PHARMACEUTICAL FORMULATION 审中-公开
标题翻译：药物制剂
公开(公告)号：WO2009125987A2
公开(公告)日：2009-10-15
申请号：PCT/KR2009001833
申请日：2009-04-09
申请人： HANALL PHARMACEUTICAL CO LTD , KIM SUNG WUK , JUN SUNG SOO , JO YOUNG GWAN , KOO JA SEONG , SUN SANG OUK , KIM JEONG TAEK , LEE AH RAM , CHOI JIN WON , JANG SEOK YOUNG , KIM BYUNG HA , KIM JIN WOOK , NAM TAE YOUNG , LEE KEEL HO
发明人： KIM SUNG WUK , JUN SUNG SOO , JO YOUNG GWAN , KOO JA SEONG , SUN SANG OUK , KIM JEONG TAEK , LEE AH RAM , CHOI JIN WON , JANG SEOK YOUNG , KIM BYUNG HA , KIM JIN WOOK , NAM TAE YOUNG , LEE KEEL HO
IPC分类号： A61K9/22 , A61K9/16 , A61K9/48 , A61K31/41 , A61K31/4184 , A61P9/12
CPC分类号： A61K31/41 , A61K31/4184
摘要： The present invention relates to a pharmaceutical formulation containing an extended-release compartment having a dihydropyridine calcium channel blocker and an immediate-release compartment having an angiotensin-2 receptor blocker. The present invention provides the pharmaceutical formulation in which the dihydropyridine calcium channel blocker and angiotensin-2 receptor blocker are separately contained in each compartment and of which release is controlled. Since each different drug contained in each different compartment of the formulation is released at a different time, the pharmaceutical formulation of the present invention minimizes the antagonism and side effects between drugs and maximizes the specific effect of the drugs. The pharmaceutical formulation by the specific combination between the two drugs according to the present invention has remarkably good effects in treating or preventing diseases compared with the single administration of each of the drugs or the simple combined administration of the drugs.
摘要翻译：本发明涉及含有具有二氢吡啶钙通道阻断剂的缓释隔室和具有血管紧张素-2受体阻断剂的速释隔室的药物制剂。本发明提供了这样的药物制剂，其中二氢吡啶钙通道阻断剂和血管紧张素-2受体阻断剂分别包含在每个隔室中并且其释放受到控制。由于制剂的每个不同区室中所含的每种不同药物在不同时间释放，本发明的药物制剂使药物之间的拮抗作用和副作用最小化，并使药物的特定作用最大化。通过本发明的两种药物之间的特定组合的药物制剂与单独施用每种药物或简单联合施用药物相比，在治疗或预防疾病方面具有显着的良好效果。

3. 发明申请

WO2009134079A9 PHARMACEUTICAL FORMULATION 审中-公开
标题翻译：药物制剂
公开(公告)号：WO2009134079A9
公开(公告)日：2010-03-11
申请号：PCT/KR2009002261
申请日：2009-04-29
申请人： HANALL PHARMACEUTICAL CO LTD , KIM SUNG WUK , JUN SUNG SOO , JO YOUNG GWAN , KOO JA SEONG , LEE AH RAM , SON JAE WOON , PARK YUN SANG , CHOI JIN WON , NAM TAE YOUNG , KIM BYUNG HA , LEE KEEL HO , LEE YOUNG JOO
发明人： KIM SUNG WUK , JUN SUNG SOO , JO YOUNG GWAN , KOO JA SEONG , LEE AH RAM , SON JAE WOON , PARK YUN SANG , CHOI JIN WON , NAM TAE YOUNG , KIM BYUNG HA , LEE KEEL HO
IPC分类号： A61K9/22 , A61K9/00 , A61K9/16 , A61K9/48 , A61K31/44 , A61K47/00
CPC分类号： A61K45/06
摘要： The present invention provides (1) a release-controlled pharmaceutical formulation including an Atorvastatin-containing early release compartment and a Losartan-containing retarded release compartment, (2) a release-controlled pharmaceutical formulation including an Atorvastatin-containing early release compartment and an Irbesartan-containing retarded release compartment, (3) a release-controlled pharmaceutical formulation including an Atorvastatin-containing early release compartment and an Olmesartan-containing retarded release compartment, (4) a release-controlled pharmaceutical formulation including an Atorvastatin-containing early release compartment and a Valsartan-containing retard release compartment, (5) a release-controlled pharmaceutical formulation including an Atorvastatin-containing early release compartment and a Telmisartan-containing retarded release compartment, (6) a release-controlled pharmaceutical formulation including an Atorvastatin-containing early release compartment and a Candesartan-containing retarded release compartment, (7) a release-controlled pharmaceutical formulation including a Pitavastatin-containing early release compartment and a Losartan-containing retarded release compartment, and (8) release-controlled pharmaceutical formulation including a Pitavastatin-containing early release compartment and an Irbesartan-containing retard release compartment. The pharmaceutical formulation of the present invention minimizes an antagonism between drugs and side effects of the drugs and maximizes unique effects of drugs because different drugs contained in different compartments in the formulation are released with a time difference. The pharmaceutical formulation of the present invention prepared by the specific combination of two drugs exhibits remarkably excellent effects of treatment or prevention of disease as compared with with a single medication or a simply combined medication.
摘要翻译：本发明提供（1）包含含阿托伐他汀的早期释放隔室和含氯沙坦的缓释隔室的释放控制药物制剂，（2）包含含阿托伐他汀的早期释放隔室和厄贝沙坦的释放控制药物制剂（3）释放控制的药物制剂，其包含含阿托伐他汀的早期释放隔室和含有奥美沙坦的缓释隔室，（4）释放控制的药物制剂，其包含含阿托伐他汀的早期释放隔室和含缬沙坦的延迟释放隔室，（5）包含含阿托伐他汀的早期释放隔室和含替米沙坦的缓释隔室的释放控制药物制剂，（6）包含含阿托伐他汀的早期释放的释放控制药物制剂 COM （7）包含匹伐他汀的早期释放隔室和含氯沙坦的缓释隔室的释放控制药物制剂，和（8）包含匹伐他汀的释放控制药物制剂早泄室和含有厄贝沙坦的缓释隔室。本发明的药物制剂使药物之间的拮抗作用和药物的副作用最小化并使药物的独特作用最大化，因为制剂中不同隔室中包含的不同药物以时间差释放。通过两种药物的具体组合制备的本发明的药物制剂与单一药物或简单组合药物相比，显示出非常优异的治疗或预防疾病的效果。

4. 发明申请

WO2009134079A2 PHARMACEUTICAL FORMULATION 审中-公开
标题翻译：药物制剂
公开(公告)号：WO2009134079A2
公开(公告)日：2009-11-05
申请号：PCT/KR2009002261
申请日：2009-04-29
申请人： HANALL PHARMACEUTICAL CO LTD , KIM SUNG WUK , JUN SUNG SOO , JO YOUNG GWAN , KOO JA SEONG , LEE AH RAM , SON JAE WOON , PARK YUN SANG , CHOI JIN WON , NAM TAE YOUNG , KIM BYUNG HA , LEE KEEL HO , LEE YOUNG JOO
发明人： KIM SUNG WUK , JUN SUNG SOO , JO YOUNG GWAN , KOO JA SEONG , LEE AH RAM , SON JAE WOON , PARK YUN SANG , CHOI JIN WON , NAM TAE YOUNG , KIM BYUNG HA , LEE KEEL HO
IPC分类号： A61K9/22
CPC分类号： A61K45/06
摘要： The present invention provides (1) a release-controlled pharmaceutical formulation including an Atorvastatin-containing early release compartment and a Losartan-containing retarded release compartment, (2) a release-controlled pharmaceutical formulation including an Atorvastatin-containing early release compartment and an Irbesartan-containing retarded release compartment, (3) a release-controlled pharmaceutical formulation including an Atorvastatin-containing early release compartment and an Olmesartan-containing retarded release compartment, (4) a release-controlled pharmaceutical formulation including an Atorvastatin-containing early release compartment and a Valsartan-containing retard release compartment, (5) a release-controlled pharmaceutical formulation including an Atorvastatin-containing early release compartment and a Telmisartan-containing retarded release compartment, (6) a release-controlled pharmaceutical formulation including an Atorvastatin-containing early release compartment and a Candesartan-containing retarded release compartment, (7) a release-controlled pharmaceutical formulation including a Pitavastatin-containing early release compartment and a Losartan-containing retarded release compartment, and (8) release-controlled pharmaceutical formulation including a Pitavastatin-containing early release compartment and an Irbesartan-containing retard release compartment. The pharmaceutical formulation of the present invention minimizes an antagonism between drugs and side effects of the drugs and maximizes unique effects of drugs because different drugs contained in different compartments in the formulation are released with a time difference. The pharmaceutical formulation of the present invention prepared by the specific combination of two drugs exhibits remarkably excellent effects of treatment or prevention of disease as compared with with a single medication or a simply combined medication.
摘要翻译：本发明提供（1）包含含阿托伐他汀的早期释放隔室和含氯沙坦的缓释隔室的释放控制药物制剂，（2）包含含阿托伐他汀的早期释放隔室和厄贝沙坦的释放控制药物制剂（3）释放控制的药物制剂，其包含含阿托伐他汀的早期释放隔室和含有奥美沙坦的缓释隔室，（4）释放控制的药物制剂，其包含含阿托伐他汀的早期释放隔室和含缬沙坦的延迟释放隔室，（5）包含含阿托伐他汀的早期释放隔室和含替米沙坦的缓释隔室的释放控制药物制剂，（6）包含含阿托伐他汀的早期释放的释放控制药物制剂 COM （7）包含匹伐他汀的早期释放隔室和含氯沙坦的缓释隔室的释放控制药物制剂，和（8）包含匹伐他汀的释放控制药物制剂早泄室和含有厄贝沙坦的缓释隔室。本发明的药物制剂使药物之间的拮抗作用和药物的副作用最小化并使药物的独特作用最大化，因为制剂中不同隔室中包含的不同药物以时间差释放。通过两种药物的具体组合制备的本发明的药物制剂与单一药物或简单组合药物相比，显示出非常优异的治疗或预防疾病的效果。

5. 发明申请

WO2009134086A3 PHARMACEUTICAL FORMULATION FOR TREATMENT OF CARDIOVASCULAR DISEASE 审中-公开
标题翻译：用于治疗心血管疾病的药物制剂
公开(公告)号：WO2009134086A3
公开(公告)日：2010-01-21
申请号：PCT/KR2009002278
申请日：2009-04-29
申请人： HANALL PHARMACEUTICAL CO LTD , KIM SUNG WUK , JUN SUNG SOO , JO YOUNG GWAN , KOO JA SEONG , LEE AH RAM , SON JAE WOON , PARK YUN SANG , KIM BYUNG HA , NAM TAE YOUNG , CHOI JIN WON
发明人： KIM SUNG WUK , JUN SUNG SOO , JO YOUNG GWAN , KOO JA SEONG , LEE AH RAM , SON JAE WOON , PARK YUN SANG , KIM BYUNG HA , NAM TAE YOUNG , CHOI JIN WON
IPC分类号： A61K9/22 , A61K9/00 , A61K9/16 , A61K9/48 , A61K31/44
CPC分类号： A61K45/06
摘要： The present invention provides (1) a release-controlled pharmaceutical formulation including a Simvastatin-containing early release compartment and a Losartan-containing retarded release compartment, (2) a release-controlled pharmaceutical formulation including a Simvastatin-containing early release compartment and an Olmesartan-containing retarded release compartment, (3) a release-controlled pharmaceutical formulation including a Simvastatin-containing early release compartment and a Valsartan-containing retarded release compartment, (4) a release-controlled pharmaceutical formulation including a Simvastatin-containing early release compartment and a Candesartan-containing retarded release compartment, (5) a release-controlled pharmaceutical formulation including a Rosuvastatin-containing early release compartment and a Losartan-containing retarded release compartment, (6) a release-controlled pharmaceutical formulation including a Rosuvastatin-containing early release compartment and an Iresartan-containing retarded release compartment, and (7) a release-controlled pharmaceutical formulation including a Rosuvastatin-containing early release compartment and a Candesartan-containing retarded release compartment. The pharmaceutical formulation of the present invention minimizes an antagonism between drugs and side effects of the drugs and maximizes unique effects of drugs because different drugs contained in different compartments in the formulation are released with a time difference. The pharmaceutical formulation of the present invention prepared by the specific combination of two drugs exhibits remarkably excellent effects of treatment or prevention of disease as compared with a single medication or a simply combined medication.
摘要翻译：本发明提供（1）包含含有辛伐他汀的早期释放室和含氯沙坦的缓释隔室的释放控制药物制剂，（2）包含含有辛伐他汀的早期释放隔室和奥美沙坦的释放控制药物制剂（3）包含含有辛伐他汀的早期释放隔室和含缬沙坦的缓释隔室的释放控制药物制剂，（4）包含含有辛伐他汀的早期释放隔室的释放控制药物制剂，以及含有Candesartan的延迟释放隔室，（5）包含含有罗苏伐他汀的早期释放隔室和含氯沙坦的缓释隔室的释放控制药物制剂，（6）包含含有罗苏伐他汀的早期释放的释放控制药物制剂隔间 d是含有Iresartan的缓释隔室，和（7）包含含有罗苏伐他汀的早期释放隔室和含有Candesartan的延迟释放隔室的释放控制药物制剂。本发明的药物制剂使药物之间的拮抗作用和药物的副作用最小化并使药物的独特作用最大化，因为制剂中不同隔室中包含的不同药物以时间差释放。通过两种药物的特定组合制备的本发明的药物制剂与单一药物或简单组合药物相比显示出非常优异的治疗或预防疾病的效果。

6. 发明申请

WO2009134086A9 PHARMACEUTICAL FORMULATION FOR TREATMENT OF CARDIOVASCULAR DISEASE 审中-公开
标题翻译：药物制剂治疗心血管疾病
公开(公告)号：WO2009134086A9
公开(公告)日：2010-03-11
申请号：PCT/KR2009002278
申请日：2009-04-29
申请人： HANALL PHARMACEUTICAL CO LTD , KIM SUNG WUK , JUN SUNG SOO , JO YOUNG GWAN , KOO JA SEONG , LEE AH RAM , SON JAE WOON , PARK YUN SANG , KIM BYUNG HA , NAM TAE YOUNG , CHOI JIN WON
发明人： KIM SUNG WUK , JUN SUNG SOO , JO YOUNG GWAN , KOO JA SEONG , LEE AH RAM , SON JAE WOON , PARK YUN SANG , KIM BYUNG HA , NAM TAE YOUNG , CHOI JIN WON
IPC分类号： A61K9/22 , A61K9/00 , A61K9/16 , A61K9/48 , A61K31/44
CPC分类号： A61K45/06
摘要： The present invention provides (1) a release-controlled pharmaceutical formulation including a Simvastatin-containing early release compartment and a Losartan-containing retarded release compartment, (2) a release-controlled pharmaceutical formulation including a Simvastatin-containing early release compartment and an Olmesartan-containing retarded release compartment, (3) a release-controlled pharmaceutical formulation including a Simvastatin-containing early release compartment and a Valsartan-containing retarded release compartment, (4) a release-controlled pharmaceutical formulation including a Simvastatin-containing early release compartment and a Candesartan-containing retarded release compartment, (5) a release-controlled pharmaceutical formulation including a Rosuvastatin-containing early release compartment and a Losartan-containing retarded release compartment, (6) a release-controlled pharmaceutical formulation including a Rosuvastatin-containing early release compartment and an Iresartan-containing retarded release compartment, and (7) a release-controlled pharmaceutical formulation including a Rosuvastatin-containing early release compartment and a Candesartan-containing retarded release compartment. The pharmaceutical formulation of the present invention minimizes an antagonism between drugs and side effects of the drugs and maximizes unique effects of drugs because different drugs contained in different compartments in the formulation are released with a time difference. The pharmaceutical formulation of the present invention prepared by the specific combination of two drugs exhibits remarkably excellent effects of treatment or prevention of disease as compared with a single medication or a simply combined medication.
摘要翻译：本发明提供了（1）释放控制的药物制剂，其包含含有辛伐他汀的早期释放隔室和含有氯沙坦的缓释隔室，（2）释放控制的药物制剂，其包含含有辛伐他汀的早期释放隔室和奥美沙坦（3）包含含有辛伐他汀的早期释放隔室和含有缬沙坦的缓释隔室的释放控制药物制剂，（4）包含含有辛伐他汀的早期释放隔室的释放控制药物制剂和（5）包含含有罗苏伐他汀的早期释放隔室和含有氯沙坦的缓释隔室的释放控制药物制剂，（6）包含含有瑞舒伐他汀的早期释放的释放控制药物制剂隔间（7）含有含瑞舒伐他汀的早释隔室和含坎地沙坦的缓释隔室的释放控制药物制剂。本发明的药物制剂使药物之间的拮抗作用和药物的副作用最小化，并使药物的独特作用最大化，因为制剂中不同药物所含的不同药物以时间差异释放。通过两种药物的特定组合制备的本发明的药物制剂与单一药物或简单组合药物相比，显示出显着优异的疾病治疗或预防效果。

7. 发明申请

WO2009125944A3 PHARMACEUTICAL PREPARATION CONTAINING NON-DIHYDROPYRIDINE CALCIUM CHANNEL BLOCKER AND ANGIOTENSIN-2 RECEPTOR BLOCKER 审中-公开
标题翻译：含有非二氢吡啶钙通道阻断剂和血管紧张素-2受体阻滞剂的药物制剂
公开(公告)号：WO2009125944A3
公开(公告)日：2009-12-03
申请号：PCT/KR2009001723
申请日：2009-04-03
申请人： HANALL PHARMACEUTICAL CO LTD , KIM SUNG WUK , JUN SUNG SOO , LEE AH RAM , SUN SANG OUK , CHOI JIN WON , JO YOUNG GWAN , KOO JA SEONG
发明人： KIM SUNG WUK , JUN SUNG SOO , LEE AH RAM , SUN SANG OUK , CHOI JIN WON , JO YOUNG GWAN , KOO JA SEONG
IPC分类号： A61K9/22 , A61K31/435
CPC分类号： A61K31/435 , A61K9/0004 , A61K9/1676 , A61K9/2018 , A61K9/2054 , A61K9/2059 , A61K9/2077 , A61K9/2081 , A61K9/209 , A61K9/2095 , A61K9/2866 , A61K9/4808 , A61K9/5078 , A61K9/5084 , A61K31/4178 , A61K31/554 , A61K45/06 , A61K2300/00
摘要： The present invention provides a pharmaceutical formulation comprising an immediate-release compartment containing an angiotensin-2 receptor blocker (ARB) as a pharmacologically active ingredient and an extended-release compartment containing a non-dihydropyridine calcium channel blocker as a pharmacologically active ingredient. Since the disclosed formulation enables the release of the two ingredients at a different time, it reduces side effects and increases the effects of the drug more than the case of separately administering the ingredients each at the same time. In addition, the formulation maximizes the effects of drug at the time of day when the complication risk of cardiovascular system diseases is highest.
摘要翻译：本发明提供一种药物制剂，其包含含有作为药理活性成分的血管紧张素-2受体阻断剂（ARB）的速释隔室和含有非二氢吡啶钙通道阻断剂作为药理活性成分的缓释隔室。由于所公开的制剂能够在不同的时间释放两种成分，因此与分别同时分别给药成分的情况相比，它减少了副作用并增加了药物的作用。另外，当心血管系统疾病的并发症风险最高时，该制剂在一天中的时间最大化药物的作用。

8. 发明申请

WO2009125944A2 PHARMACEUTICAL PREPARATION CONTAINING NON-DIHYDROPYRIDINE CALCIUM CHANNEL BLOCKER AND ANGIOTENSIN-2 RECEPTOR BLOCKER 审中-公开
标题翻译：含有非二氢脯氨酸钙通道阻断剂和血管紧张素-2受体阻断剂的药物制剂
公开(公告)号：WO2009125944A2
公开(公告)日：2009-10-15
申请号：PCT/KR2009001723
申请日：2009-04-03
申请人： HANALL PHARMACEUTICAL CO LTD , KIM SUNG WUK , JUN SUNG SOO , LEE AH RAM , SUN SANG OUK , CHOI JIN WON , JO YOUNG GWAN , KOO JA SEONG
发明人： KIM SUNG WUK , JUN SUNG SOO , LEE AH RAM , SUN SANG OUK , CHOI JIN WON , JO YOUNG GWAN , KOO JA SEONG
IPC分类号： A61K9/22 , A61K31/435
CPC分类号： A61K31/435 , A61K9/0004 , A61K9/1676 , A61K9/2018 , A61K9/2054 , A61K9/2059 , A61K9/2077 , A61K9/2081 , A61K9/209 , A61K9/2095 , A61K9/2866 , A61K9/4808 , A61K9/5078 , A61K9/5084 , A61K31/4178 , A61K31/554 , A61K45/06 , A61K2300/00
摘要： The present invention provides a pharmaceutical formulation comprising an immediate-release compartment containing an angiotensin-2 receptor blocker (ARB) as a pharmacologically active ingredient and an extended-release compartment containing a non-dihydropyridine calcium channel blocker as a pharmacologically active ingredient. Since the disclosed formulation enables the release of the two ingredients at a different time, it reduces side effects and increases the effects of the drug more than the case of separately administering the ingredients each at the same time. In addition, the formulation maximizes the effects of drug at the time of day when the complication risk of cardiovascular system diseases is highest.
摘要翻译：本发明提供了包含含有作为药理活性成分的血管紧张素-2受体阻断剂（ARB）的立即释放室和含有非二氢吡啶类钙通道阻滞剂作为药理活性成分的延长释放室的药物制剂。由于所公开的配方使得能够在不同时间释放两种成分，所以与同时分别施用各成分的情况相比，其降低副作用并增加药物的效果。此外，当心血管系统疾病的并发症风险最高时，该制剂使药物的效果最大化。

9. 发明申请

WO2009134057A3 PHARMACEUTICAL FORMULATION CONTAINING ANGIOTENSIN-II RECEPTOR BLOCKER 审中-公开
标题翻译：含有血管紧张素II受体阻断剂的药物制剂
公开(公告)号：WO2009134057A3
公开(公告)日：2010-01-21
申请号：PCT/KR2009002225
申请日：2009-04-28
申请人： HANALL PHARMACEUTICAL CO LTD , KIM SUNG WUK , JUN SUNG SOO , JO YOUNG GWAN , KOO JA SEONG , LEE AH RAM , SON JAE WOON , KIM JEONG TAEK
发明人： KIM SUNG WUK , JUN SUNG SOO , JO YOUNG GWAN , KOO JA SEONG , LEE AH RAM , SON JAE WOON , KIM JEONG TAEK
IPC分类号： A61K9/22 , A61K9/00 , A61K9/20 , A61K9/48
CPC分类号： A61K31/00 , A61K9/2081 , A61K9/2866 , A61K31/41 , A61K31/4178
摘要： The present invention provides a pharmaceutical formulation containing an angiotensin-II receptor blocker and a release-control material as a pharmacologically active ingredient and a pharmaceutical formulation comprising an immediate-release compartment and an extended-release compartment. The immediate-release compartment contains an agent as a pharmacologically active ingredient for preventing and inhibiting hepatitis and the extended-release compartment has an angiotensin-II receptor blocker as a pharmacologically active ingredient. The formulation of the present invention maximizes the effectiveness on pharmacologically and clinically lowering blood pressure and preventing complications when taking the formulation, helps to avoid interaction with a drug which is metabolized by the same enzyme in the liver, and prevents and inhibits the incidence of drug-induced hepatitis which is caused by drug administration for a long time.
摘要翻译：本发明提供含有血管紧张素-II受体阻断剂和作为药理活性成分的释放控制材料的药物制剂以及包含立即释放室和延长释放室的药物制剂。立即释放隔室含有作为预防和抑制肝炎的药理学活性成分的药剂，并且延长释放室具有血管紧张素-II受体阻断剂作为药理学活性成分。本发明的制剂使药物和临床上降低血压的效果最大化并且在服用制剂时预防并发症，有助于避免与由肝脏中的相同酶代谢的药物相互作用，并且预防和抑制药物的发生引起的药物长期引起的肝炎。

10. 发明申请

WO2009127922A2 PHARMACEUTICAL FORMULATION FOR TREATING CARDIOVASCULAR DISEASE 审中-公开
标题翻译：用于治疗心血管疾病的药物制剂
公开(公告)号：WO2009127922A2
公开(公告)日：2009-10-22
申请号：PCT/IB2009000331
申请日：2009-02-23
申请人： HANALL PHARMACEUTICAL CO LTD , KIM SUNG WUK , JUN SUNG SOO , KOO JA SEONG , KIM JIN WOOK , PARK SUN WOO , JANG SEOK YOUNG , LEE SANG JU , JO YOUNG GWAN , LEE JUN YOUNG
发明人： KIM SUNG WUK , JUN SUNG SOO , KOO JA SEONG , KIM JIN WOOK , PARK SUN WOO , JANG SEOK YOUNG , LEE SANG JU , JO YOUNG GWAN , LEE JUN YOUNG
IPC分类号： A61K9/52 , A61K9/22 , A61K9/28 , A61K31/44 , A61K47/38 , A61P9/00
CPC分类号： A61K31/44 , A61K9/209
摘要： The present invention provides a pharmaceutical formulation containing an immediate-release compartment and an extended-release compartment. The immediate-release compartment comprises a statin lipid-lowering drug, its isomer, or its pharmaceutically acceptable salt as a pharmacologically active ingredient and the extended-release compartment contains a dihydropyridine calcium channel blocker, its isomer, or its pharmaceutically acceptable salt as a pharmacologically active ingredient. The combined formulation of immediate-release, statin lipid-lowering drug and extended-release dihydropyridine calcium channel blocker, is pharmacologically, clinically, scientifically, and economically more useful than the single formulation of each of the drugs or a simple combination of the drugs, in preventing and treating cardiovascular disease, cardiopulmonary disease, pulmonary disease, or kidney disease in patients with metabolic syndrome and insulin resistance and patients with diabetes or suspected prediabetes. médicamentsThe formulation of the present invention allows different release times for the statin lipid-lowering drug and the dihydropyridine calcium channel blocker, and thus prevents mutual antagonism and side effects between the two drugs, and provides easy administration for patients simultaneously taking the two drugs simultaneously.
摘要翻译：本发明提供了含有速释隔室和缓释隔室的药物制剂。速释隔室包含作为药理活性成分的他汀类降脂药，其异构体或其药学上可接受的盐，并且缓释室包含二氢吡啶类钙通道阻断剂，其异构体或其药学上可接受的盐，作为药理学有效成分。速释他汀类降脂药和缓释二氢吡啶钙通道阻滞剂的组合制剂在药理学，临床，科学和经济上比每种药物的单一制剂或药物的简单组合更有用，用于预防和治疗代谢综合征和胰岛素抵抗患者中的心血管疾病，心肺疾病，肺病或肾病以及糖尿病或怀疑前驱糖尿病患者。本发明的制剂允许他汀类降脂药和二氢吡啶类钙通道阻滞剂的释放时间不同，从而防止两种药物之间的相互拮抗和副作用，并且为同时服用两种药物的患者提供了容易的给药。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式